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What is known 
Background 
Palliative care has predominately focussed on management of patients with cancer at the end-of-life 
(EOL). The End-of-Life Care Strategy (1) and other National Institute for Health and Care Excellence 
(NICE) guidance has demanded that Palliative Care embrace all patients with life-limiting disease, 
irrespective of diagnosis. In addition focus of care should not be limited to the last days or weeks of 
life but should extend earlier in the patient pathway.  
Non-malignant lung disease has a high mortality and symptom burden and encompasses various 
pathologies including chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), 
cystic fibrosis (CF), pulmonary hypertension, neuromuscular disorders and infections. The physical 
and psychosocial needs of patients with these chronic lung diseases at end-of-life are comparable to 
those with lung cancer (2). This article will focus on COPD (which encompasses a range of primarily 
bronchial obstructive disorders, e.g. chronic bronchitis and emphysema), ILD (a large group of 
progressive disorders causing lung parenchymal fibrosis which include idiopathic pulmonary fibrosis, 
connective tissue disease and asbestosis) and CF (an autosomal recessive genetic disorder affecting 
chloride ion transportation).  
COPD, ILD and CF are life-limiting, non-curable illnesses. Treatments for these conditions may be 
primarily aimed at disease modification (slowing or halting progression of disease) or purely at 
palliation with improvement of symptoms and quality of life (QoL). Current research has principally 
evaluated treatments aimed at disease modification. Lung transplantation is increasingly an option 
for some patients within these groups and this unique situation highlights the dichotomy of 
palliation and preparation for death, balanced with active management and potential ‘cure’ (3). 
Despite the considerable symptom burden and life-limiting nature of these diseases, uncertainty in 
predicting prognosis can lead to poor communication about palliative and end-of-life care and often 
limited access to specialist palliative care services (4). 
COPD is the  leading cause of death worldwide with over 25,000 people dying each year in the UK. 
Local palliative care services might expect to be involved for a significant proportion of these 
patients. In contrast, there are about 2,000 deaths from ILD and around 100 deaths from CF each 
year (with the majority being adults). Many of these patients are cared for and die in secondary or 
tertiary referral centres. As palliative care expands to encompass these diseases, more referrals will 
be made for symptom management and end of life care requesting local palliative care at various 
points in the patient’s illness.  
It is vital that palliative and respiratory services develop models of care that promote joint working 
between teams. Palliative care specialists may need to be involved at an early stage to enhance 
symptom management and jointly support advance care planning, alongside disease-directed 
therapy led by the respiratory team. When symptoms improve, the patient does not need 
continuous specialist palliative care input, but might dip in and out of the service. For example 
patients can experience severe nausea and breathlessness associated with antibiotic management of 
infective exacerbations. At the end stage of their disease, which can be difficult to define, increased 
patient and family support from the Specialist Palliative Care Team (SPCT) may be required with on-
going input from respiratory physicians. It is important to ensure access to appropriate expertise to 
guide care and also to acknowledge where teams have been involved in caring for patients over a 
prolonged period of time (years). Joint working enables the patients to move within the services as 
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their needs dictate and has the advantage that as patients approach EOL they already have a 
relationship and trust the palliative care service. Joint working across hospital and community 
services is vital to facilitate real choice regarding place of care for these patients at EOL (5). 
 
Prognosis, prognostication 
Although COPD, ILD and CF have different aetiologies, affect people of different ages and can have 
differing disease trajectories, they tend to be slowly progressive illness, punctuated by infective 
exacerbations. Patients have often coped with their illness for many years. In COPD, for example, 
attempts to prognosticate and identify patients in last year of life based on disease parameters have 
been largely unsuccessful (6, 7). In practice patient-related factors such as increasing breathlessness 
between exacerbations, weight loss, and increasing anxiety are often associated with EOL. Table 1 
lists the Gold Standards Framework (GSF) Prognostic Indicator Guidance for COPD, although it has 
not been formally validated in these patient groups, on-going use implies semi-validation in clinical 
practice.  
In view of the progressive nature of these illnesses, and the difficulty with prognostication, it is 
important a care strategy is implemented early and is adaptable throughout the course of the illness. 
Treatment discussions and advance care planning are vital. Patients may require invasive/non-
invasive ventilation at different time points and/or be assessed for lung transplantation, although, 
even if accepted many become ineligible or die whilst awaiting a suitable transplant. Appropriate 
escalation of treatment may be successful earlier in the patient’s illness but become less effective 
and increasingly burdensome as disease progresses. Initially the best form of symptom management 
is disease-modifying therapies. A combination of disease and symptom-directed treatment will be 
needed during the course of the patient’s illness shifting to a primary focus of symptom 
management. The difficulty in distinguishing between a severe exacerbation and dying presents 
palliative physicians, especially in the hospice setting, with both a dilemma regarding how “active” to 
be in managing exacerbations and the need to have clearly defined admission and onward referral 
criteria with on-going support from respiratory physicians. 
 
 
Table 1: Gold Standards Framework (GSF) Prognostic Indicator Guidance for COPD (8) 
Chronic Obstructive Pulmonary Disease (COPD). 
At least two of the indicators below: 
Disease assessed to be severe (e.g. FEV1 <30% predicted) 
Recurrent hospital admissions (at least 3 in last 12 months due to COPD) 
Fulfils long term oxygen therapy criteria 
MRC grade 4/5 – shortness of breath after 100 metres on the level of confined to house 
Signs and symptoms of right heart failure 
Combination of other factors – i.e. anorexia, previous ITU/NIV, resistant organisms 
More than 6 weeks of systemic steroids for COPD in preceding 6 months. 
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What are the supportive and palliative care needs of people with non-malignant lung disease? 
Despite medical therapy, around 75% of individuals with moderate to severe COPD experienced 
dyspnoea (9), with most not achieving relief from dyspnoea in the last 6 months of life. Dyspnoea 
causes social isolation, difficulty performing activities of daily living and impairs QoL. Prevalence of 
anxiety and depression in these patients may reach 80% (10). Pain, breathlessness, and fatigue are 
frequent and comparable to cancer and heart disease cohorts (11).  In addition the information 
needs of these patients are great (4, 12). One qualitative study showed that patients’ understanding 
of COPD was poor, with a lack of awareness of both the progressive nature of their disease and that 
they might die of COPD. Despite this the patients were concerned that their disease might progress 
and were frightened that they would die of breathlessness or suffocation. None of the patients in 
this study had discussed these fears with any health care professional (13). Not only does COPD 
affect the patient, but it also has been shown to impact on the carer, with loss of personal liberty 
and dignity, the need to adapt to the effects of the disease and with the carer taking on multiple 
roles, they also experienced some of the same losses as the patient and appeared enmeshed with 
the illness (14).  
In their last year of life, most patients with ILD experienced severe breathlessness, cough, fatigue, 
depression, anxiety, chest pain and an impaired QoL (15, 16). Qualitative research describes how 
dyspnoea and cough impact on every part of the lives of ILD patients and carers, and patients 
expressed frustration and anger at their limited independence and the impact of illness on family 
relationships. ILD patients and carers report a lack of information sharing and although they may 
know that the disease is terminal they have a poor understanding of prognosis or what might occur 
at end-of-life (17, 18).  
Symptoms are also frequent in patients with CF, as 84% had pain, 83% cough and 64% 
breathlessness (19). Qualitative interviews describe similar themes regarding lack of information and 
the challenge of maintaining hope whilst planning for death (20). Although CF caregivers identified 
many symptoms, they did not think they could be controlled and were concerned about the role of 
opioids such as morphine and their potential for hastening death (21).  
Despite the poor prognosis and symptom burden of non-malignant lung disease, there is inequitable 
access to specialist palliative care services, often with no formal process for identifying patients at 
end of life (22). 
 
Evidence base for specific symptom interventions 
Although there is a range of symptoms experienced by patients with non-malignant lung disease, we 
have focused on management of dyspnoea. A combination of non-pharmacological and 
pharmacological interventions is needed and it is important that self-help strategies are taught early 
and reinforced. The mainstay of treatment is physiotherapy (which may need to be intensive and 
sustained) and psychology. Even in advanced disease, evidence for the most cost-effective care in 
COPD remains that for pulmonary rehabilitation and stopping smoking, with targeted vaccinations 
(23).  
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A Cochrane review of non-pharmacological measures for dyspnoea in advanced disease, showed 
breathing training, walking aids, neuro-electrical muscle stimulation and chest wall vibration to be 
effective (24) with no evidence for distractive auditory stimulation, relaxation, fan, counselling and 
support with breathing-relaxation training, case management and psychotherapy. One recent study 
supports handheld fan therapy to reduce the sensation of breathlessness (25). 
Evidence increasingly supports the benefits of short –term opioids in treating breathlessness in 
COPD patients (26-28). Data on longer term efficacy and safety, and data for COPD patients with 
type 2 respiratory failure are lacking. Given the prognostic uncertainties our view is that it is prudent 
to use opioids in patients who: are breathless at rest; have otherwise severe breathlessness 
unresponsive to other interventions; or are clearly at EOL (29). Views vary as to the best way of 
initiating and titrating opioids for these patients (26,29). 
A recent Cochrane systematic review found no evidence that benzodiazepines relieved dyspnoea in 
patients with COPD. They caused more drowsiness than placebo, but less than morphine. When 
opioids and non-pharmacological measures are ineffective, benzodiazepines are often trialled 
especially if anxiety is problematic (30). 
Oxygen is beneficial in hypoxaemic COPD patients and Long term Oxygen Therapy (LTOT) reduces 
the risk of developing cor pulmonale. Oxygen may relieve dyspnoea in patients with COPD who are 
mildly or non-hypoxaemic, but this should be individualised (31) as there are no predictive factors to 
determine who will benefit. In a recent international study, palliative oxygen and medical air both 
relieved dyspnoea and improved QoL to a similar, albeit small degree (32). Thus a 3–4 day trial of 
oxygen or medical air could be used to assess patients who would benefit. 
These review finding are supported by the Canadian Thoracic Society clinical practice guideline for 
managing dyspnoea in patients with advanced COPD (33). In a recent hospital based study, dyspnoea 
was improved after a palliative care consultation, with opioids ± benzodiazepines associated with 
improvement in dyspnoea (34). 
The use of bi-level non-invasive ventilation (NIV) in COPD at EOL is controversial. Opinions vary as to 
whether NIV is helpful in managing distressing symptoms at EOL or unhelpful, being a significant 
barrier to communication (35, 36). Goals of care need to be proactively established with a clear 
management plan, especially if patients are admitted to a hospice (36). 
For patients with ILD, the evidence base for symptom management is poor. A recent systematic 
review shows strong evidence for the use of pulmonary rehabilitation and pirfenidone to improve 
functional outcomes and moderate evidence for both sildenafil and pulmonary rehabilitation in 
improving QoL. (37).  
 
What is unknown? 
Although limited aspects of assessment, management and prognostication are known and described 
above, there is much that remains unknown and these need to be explored further, especially in 
individual diseases. The optimal model(s) of service delivery remain unknown and although several 
different models are being trialled in clinical practice, these need formal evaluation. 
Invited submission to Special Edition Palliative Medicine  
 
How to deliver the service 
Service delivery models currently in use include ring-fencing some time in an already established 
multidisciplinary team (MDT), setting up a new subspecialised MDT or a subspecialised clinic. 
Negotiating that part of a existing respiratory MDT meeting is focussed towards palliative issues with 
the SPCT attending for this section is probably the most manageable first step. Both inpatients and 
outpatients with palliative care needs can be discussed, direct referrals can be made and patients 
known to the SPCT can be brought back to the MDT. Attending the whole of the MDT, may be 
needed in the first instance whilst teams are getting to know each other’s remit, role and what the 
SPCT can offer, but once this is established supporting some of the MDT is a better use of limited 
resources. Initial joint review of inpatients by both teams, with the SPCT seen as part of the wider 
MDT has also been important, together with opportunities to meet patients early when symptoms 
are problematic, to develop rapport for increased input at later stage. This is a model used in 
establishing SPCT input for CF patients in the Royal Brompton Hospital, UK. Another MDT model is to 
set up a new fortnightly MDT, specifically for a group of patients, such as very severe COPD. This 
could bring together respiratory, palliative and microbiology consultants to optimise the disease-
directed and symptom management plans. This is a model that was used in establishing joint 
working between the palliative care and respiratory teams in Barnsley, UK (38).  
St Joseph’s Hospice, UK has set up a clinic specifically to meet needs for COPD patients - liaising with 
their local respiratory clinicians. A ‘Hospital-to-Home’ case-conference model of care for patients no 
longer having disease modifying treatment, with a focus on ascertaining preferred place of care and 
death and facilitating transition of care from tertiary referral to community setting, is currently being 
evaluated for patients with ILD at the Royal Brompton Hospital. This may help in information sharing 
between professionals. 
The model used, would depend on patient numbers, their needs and the resources available. By 
integrating the service with the respiratory team, there can be joint learning as palliative care 
physicians will not be experts in non-malignant lung disease and respiratory physicians will often 
benefit from better understanding of what modern palliative care is and what it can offer. By 
developing the teams in tandem, trust and knowledge is gained and the patients benefit, by seeing 
the most appropriate clinician for them at that time. 
 
Implications for clinical practice  
We need to develop effective working between the hospital, hospice and community SPCTs, with 
respiratory services backup, to ensure seamless delivery of care in patients with life-limiting non-
malignant lung disease. This may involve a shift in traditional working practice as patients are often 
very actively treated right up to death, including with NIV and being considered for transplant which 
represents the potential for ‘curative’ treatment. Furthermore, the physiology of the underlying 
diseases is different and may require changes to type/dose of medication for symptom control. As 
access to palliative care is variable and underutilised for this cohort of patients, a better 
understanding of and subsequent reduction in the barriers to referral is vital. This can be improved 
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by increasing access to the SPCT by increasing visibility on the wards, informal routes of access to 
advice and a timely response to referrals (39).   
Comprehensive supportive care is needed for these patients, with maximal pharmacotherapy 
directed at the underlying disease, pulmonary rehabilitation, occupational therapy, psychosocial 
supports, nutritional support, as well as consideration of specific palliative pharmacotherapy such as 
the use of opioids, benzodiazepines and potentially oxygen. 
 
Implication for future research 
Although there are studies focused on the palliative care of non-malignant lung disease there is still 
a lack of large high quality trials of pharmacological (opioids and benzodiazepines) and non-
pharmacological interventions and their combinations. Recent articles have highlighted some key 
areas for further research (40-42), which are highlighted in table 2. Evaluation of these alongside the 
efficacy and cost-effectiveness of models of care are needed.  
 
Table 2: Key areas for further research. 
Key areas for further research 
Appropriately designed and powered studies to evaluate pharmacological and non-pharmacological 
therapies in these disease groups 
Is there a class effect from opioids 
What is the role of rapid-onset opioids 
Is there a subgroup of people who gain net benefit from oxygen therapy 
Oxygen for breathlessness during or after movement 
What is the role of combination therapies, e.g. oxygen alongside opioids and/or benzodiazepines 
Develop a consensus on the use of validated outcome scales and use of primary endpoints related to 
symptom control and quality of life 
Develop staging instruments to identify ILD patients in the last year of life 
Evaluate the most cost-effective model of care for non-malignant lung disease patients towards the 
end of life 
Explore the perceived barriers to joint working between non-malignant lung disease and palliative 
care services 
Explore the involvement of palliative care early in the patients’ disease to support symptom 
management 
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